« Return to News | Clinical Intelligence

Soligenix anthrax vaccine shows robust stability

Sunday, January 22, 2012 11:17 AM

Soligenix, a development-stage biopharmaceutical company, shared results from long-term stability studies of its proprietary DNI (dominant negative inhibitor) anthrax rPA (recombinant protective antigen) subunit protein vaccine, known as SGX204.

SGX204 is a hyperimmunogenic derivative of PA and is being developed as a vaccine to protect against anthrax disease either as a pre-exposure prophylactic vaccine or post-exposure vaccine.

Positive stability was demonstrated when DNI rPA was subjected to temperatures as high as 70 degrees Celsius for one month.  In that case, DNI rPA retained native configuration with no evidence of denaturation that typically occurs in water buffers under the same thermal conditions.

Long-term stability of DNI rPA was also demonstrated after refrigerated storage for more than seven years. More importantly, when DNI rPA was combined with a potent adjuvant formulation, animals vaccinated with the combination developed high titer neutralizing antibodies that confer protection against anthrax disease.

"We are very excited about these extraordinary stability results," stated Robert N. Brey, Ph.D., chief scientific officer of Soligenix. "Further, SGX204 is highly immunogenic and thereby offers the potential for complete immunization with just one or two doses. As with any biodefense product, our goal is to have SGX204 stockpiled by the U.S. government."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.